Major drugmakers are planning to meet with President Donald Trump next week at the White House as part of the industry’s ...
Corbus' CRB-701 shows 23% response rate in early cancer trial, but shares fall after some patients with prior Padcev ...
Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan ...
About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...
West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...
Bambusa Therapeutics raises $90M Series A for bispecific antibodies, led by RA Capital. Founded by BioNTech veterans, plans ...
David Schenkein will step down from Agios Pharmaceuticals ’ board of directors at the end of the month “to devote more ...
Moderna is working on restoring investors' faith that its Covid-19 vaccine was not a one-hit-wonder. It also has to show it ...
A series of actions by President Donald Trump's administration have provoked profound anxiety among academic labs that ...
Agios' Pyrukynd met primary endpoint in Phase 3 study for children with PK deficiency who don't need regular transfusions, ...
The drugmaker is stopping development of OPB-111077, an oral STAT inhibitor, for hematological cancers in the US. It also terminated several cancer drugs it was developing in Japan for cancers like ...
Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 targeting immunotherapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback